Want to see IN:ORTINGLOBE full AI Analyst Report?
Top Page
Ortin Global Ltd
(ORTINGLOBE)
Select Model
Select Model
Rating:46Neutral
Price Target:
₹15.00
▲(29.87% Upside)
Action:Reiterated
Date:09/10/26
The score is weighed down primarily by weak financial performance—severe margin collapse, large losses, and ongoing negative operating cash flow alongside rising leverage. Technical indicators are neutral-to-slightly weak and do not offset the fundamentals, while valuation is constrained by a loss-making (negative P/E) profile and no dividend yield data.
Positive Factors
FY2026 Revenue Growth
The sharp FY2026 revenue increase indicates that the company achieved meaningful top-line expansion over the prior year. If management can stabilize margins and control costs, this larger revenue base could support improved operating leverage and provide a foundation for future recovery.
Negative Factors
Severe Profitability Collapse
Profitability deterioration is severe, with gross profit turning negative and operating and net losses reaching very large levels relative to revenue. Such extreme margin pressure undermines the quality of reported growth, increases funding needs, and makes a near-term earnings recovery dependent on major cost and business-model improvements.
Read all positive and negative factors
Positive Factors
Negative Factors
FY2026 Revenue Growth
The sharp FY2026 revenue increase indicates that the company achieved meaningful top-line expansion over the prior year. If management can stabilize margins and control costs, this larger revenue base could support improved operating leverage and provide a foundation for future recovery.
Read all positive factors
Ortin Global Ltd (ORTINGLOBE) vs. iShares MSCI India ETF (INDA)
Market Cap
₹124.49M
Dividend YieldN/A
Average Volume (3M)1.48K
Price to Earnings (P/E)―
Beta (1Y)0.40
Revenue Growth-69.71%
EPS Growth1.73%
CountryIN
Employees3
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-1.12
Shares Outstanding8,131,392
10 Day Avg. Volume1,155
30 Day Avg. Volume1,480
Financial Highlights & Ratios
PEG Ratio1.24
Price to Book (P/B)9.31
Price to Sales (P/S)114.55
P/FCF Ratio-20.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Ortin Global Ltd Business Overview & Revenue Model
Company Description
Ortin Global Ltd., established in 1986 and headquartered in Hyderabad, India, is an Indian enterprise specializing in the manufacturing and trading of pharmaceuticals, drugs, and their intermediates. The company, formerly known as Ortin Laboratori...
How the Company Makes Money
null...
Ortin Global Ltd Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
38
Negative
Cash Flow
20
Very Negative
| Breakdown | TTM | Mar 2025 | Mar 2024 |
|---|---|---|---|
Income Statement | |||
| Total Revenue | 767.00K | 1.00M | 3.42M |
| Gross Profit | -1.07M | -1.52M | 1.28M |
| EBITDA | -8.92M | -7.21M | -8.23M |
| Net Income | -9.03M | -7.40M | -8.46M |
Balance Sheet | |||
| Total Assets | 0.00 | 46.47M | 37.81M |
| Cash, Cash Equivalents and Short-Term Investments | 6.06M | 6.06M | 3.74M |
| Total Debt | 0.00 | 10.05M | 2.50M |
| Total Liabilities | -12.37M | 34.10M | 18.03M |
| Stockholders Equity | 12.37M | 12.37M | 19.77M |
Cash Flow | |||
| Free Cash Flow | -7.75M | -5.60M | -4.14M |
| Operating Cash Flow | -7.75M | -5.62M | -4.10M |
| Investing Cash Flow | 410.00K | 390.00K | -36.00K |
| Financing Cash Flow | 6.79M | 7.55M | 3.28M |
Ortin Global Ltd Technical Analysis
Positive
11.55
Price Trends
15.48
Negative
15.43
Negative
14.95
Positive
Market Momentum
-0.02
Negative
50.77
Neutral
48.83
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ORTINGLOBE, the sentiment is Positive. The current price of 11.55 is below the 20-day moving average (MA) of 15.18, below the 50-day MA of 15.48, and below the 200-day MA of 14.95, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 50.77 is Neutral, neither overbought nor oversold. The STOCH value of 48.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:ORTINGLOBE.
Ortin Global Ltd Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | ₹1.65B | 11.98 | ― | 0.70% | 4.29% | 2.40% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
49 Neutral | ₹501.28M | -1.44 | ― | 0.28% | -22.27% | -291.72% | |
47 Neutral | ₹508.72M | 124.42 | ― | ― | 9.31% | -82.71% | |
46 Neutral | ₹124.49M | -14.61 | ― | ― | -69.71% | 1.73% | |
45 Neutral | ₹522.36M | -0.29 | ― | 0.67% | -39.80% | -452.04% | |
42 Neutral | ₹330.17M | -1.98 | ― | 0.67% | -95.17% | 50.09% |
* General Sector Average
IN:ORTINGLOBE
Ortin Global Ltd
16.07
3.32
26.04%
IN:BIOFILCHEM
Biofil Chemicals & Pharmaceuticals Ltd.
36.83
-6.76
-15.51%
IN:LASA
Lasa Supergenerics Ltd.
6.59
-5.03
-43.29%
IN:MANGALAM
Mangalam Drugs & Organics Ltd.
34.83
-42.11
-54.73%
IN:PAR
Par Drugs and Chemicals Limited
141.08
27.51
24.22%
IN:VIVIMEDLAB
Vivimed Labs Limited
6.19
1.29
26.33%
Ortin Global Ltd Corporate Events
Ortin Global Closes Trading Window Ahead of June-Quarter Results
Jun 24, 2026
Ortin Global Limited has announced the closure of its trading window from July 1, 2026, until 48 hours after the announcement of its unaudited financial results for the quarter ended June 30, 2026. The restriction applies to designated persons, th...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.